Viridian Therapeutics
VRDN
33 hedge funds and large institutions have $84.5M invested in Viridian Therapeutics in 2021 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 3 closing their positions.
367% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 3
131% more capital invested
Capital invested by funds: $36.6M → $84.5M (+$47.9M)
84.79% more ownership
Funds ownership: 56.98% → 141.77% (+85%)
50% more funds holding
Funds holding: 22 → 33 (+11)
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ABG
Ally Bridge Group
New York
|
+$12.7M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$10.8M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$8.72M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$8.5M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$6.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$2.61M |
| 2 |
Renaissance Technologies
New York
|
-$752K |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$573K |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$502K |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$253K |
VRDN Hedge Fund Activity: Q1 2021 in Review
33 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q1 2021, worth a combined $84.5M — up 131% from $36.6M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new VRDN positions and 3 closed out — a net gain of 11 holders — while 7 added to existing stakes and 6 trimmed.
The largest buyer was Ally Bridge Group, opening a new position worth an estimated $12.7M. The largest seller was RA Capital Management, cutting an estimated $2.61M.
- 33 institutional investors held Viridian Therapeutics (VRDN) as of Q1 2021, up from 22 in Q4 2020.
- Funds reported $84.5M of Viridian Therapeutics stock for Q1 2021, up 131% quarter-over-quarter.
- 14 funds opened new Viridian Therapeutics positions in Q1 2021 and 3 closed out, a net change of +11 holders.
- The largest Viridian Therapeutics buyer in Q1 2021 was Ally Bridge Group, an estimated $12.7M added.
- The largest Viridian Therapeutics seller in Q1 2021 was RA Capital Management, an estimated $2.61M sold.
Based on aggregated 13F filings for Q1 2021.